Monte Rosa Therapeutics Inc

NASDAQ GLUE

Data sourced from

and

Daily

Download Data

Monte Rosa Therapeutics Inc Price to Sales Ratio (P/S) on June 03, 2024: 24.79

Monte Rosa Therapeutics Inc Price to Sales Ratio (P/S) is 24.79 on June 03, 2024, a NA change year over year. The price to sales ratio compares the market price per share of a company's stock to its sales revenue per share. It is calculated by dividing the market capitalization by the revenue, divided by the number of outstanding shares. This ratio provides insights into the market's valuation of a company's sales revenue. A higher ratio suggests that investors are willing to pay a higher price for each unit of sales revenue, indicating positive market sentiment and expectations for future revenue growth.

Monte Rosa Therapeutics Inc 52-week high Price to Sales Ratio (P/S) is 32.39 on May 17, 2024, which is 30.65% above the current Price to Sales Ratio (P/S).
Monte Rosa Therapeutics Inc 52-week low Price to Sales Ratio (P/S) is 24.79 on June 03, 2024, which is 0.00% below the current Price to Sales Ratio (P/S).
Monte Rosa Therapeutics Inc average Price to Sales Ratio (P/S) for the last 52 weeks is 26.81.

NASDAQ: GLUE

Monte Rosa Therapeutics Inc

CEO	Dr. Markus Warmuth M.D.
IPO Date	June 24, 2021
Location	United States
Headquarters	645 Summer Street, Boston, MA, United States, 02210
Employees	130
Sector	Healthcare
Industry	Biotechnology

Description

Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1"/NLRP3 driven inflammatory diseases. It also develops CDK2 to treat ovarian, uterine, and breast cancers. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.

Key trends